(Q42614935)

English

Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial

scientific article published on 13 March 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

phase III clinical trial

0 references

adaptive radiation therapy

0 references

quality of life

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

Sophie D. Fosså

6

object named as

Sophie Fosså

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

author name string

Per Fransson

1

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Jo-Asmund Lund

2

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Jan-Erik Damber

3

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Olbjörn Klepp

4

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Fredrik Wiklund

5

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Anders Widmark

7

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Scandinavian Prostate Cancer Group Study 7

8

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Swedish Association for Urological Oncology 3

9

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

13 March 2009

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

370-380

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970027-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality of life and symptoms in a randomized trial of radiotherapy versus deferred treatment of localized prostate carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970027-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970027-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Incidence of Late Rectal and Urinary Toxicities After Three-Dimensional Conformal Radiotherapy and Intensity-Modulated Radiotherapy for Localized Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970027-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Conventional treatments of localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970027-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970027-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970027-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial Infarctions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970027-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970027-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant androgen deprivation impacts late rectal toxicity after conformal radiotherapy of prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970027-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of neoadjuvant androgen ablation and other factors on late toxicity after external beam prostate radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970027-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality of life and satisfaction with outcome among prostate-cancer survivors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970027-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970027-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Interpreting the significance of changes in health-related quality-of-life scores.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970027-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970027-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Neo-adjuvant and adjuvant hormone therapy for localised prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970027-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970027-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Five-year prospective patient evaluation of bladder and bowel symptoms after dose-escalated radiotherapy for prostate cancer with the BeamCath technique

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970027-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Late rectal symptoms and quality of life after conformal radiation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970027-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Health-related quality of life in patients with locally advanced prostate cancer after 76 Gy intensity-modulated radiotherapy vs. 70 Gy conformal radiotherapy in a prospective and longitudinal study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970027-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined androgen blockade in advanced prostate cancer: looking back to move forward

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970027-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Health outcomes after external-beam radiation therapy for clinically localized prostate cancer: results from the Prostate Cancer Outcomes Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970027-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970027-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970027-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Distress and social dysfunction following prostate cancer treatment: a longitudinal cross-cultural comparison of Japanese and American men.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970027-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Patient satisfaction with treatment decisions for clinically localized prostate carcinoma. Results from the Prostate Cancer Outcomes Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970027-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970027-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970027-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970027-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-Term Results of the M. D. Anderson Randomized Dose-Escalation Trial for Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970027-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970027-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970027-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(09)70027-0

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42614935&oldid=1962860397"